233 related articles for article (PubMed ID: 25578210)
1. Emerging drugs for the treatment of cervical cancer.
Serrano-Olvera A; Cetina L; Coronel J; Dueñas-González A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):165-82. PubMed ID: 25578210
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of current and emerging treatments for cervical cancer.
Duenas-Gonzalez A; Gonzalez-Fierro A
Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
[No Abstract] [Full Text] [Related]
3. New molecular targets against cervical cancer.
Duenas-Gonzalez A; Serrano-Olvera A; Cetina L; Coronel J
Int J Womens Health; 2014; 6():1023-31. PubMed ID: 25525394
[TBL] [Abstract][Full Text] [Related]
4. New pharmacotherapy options for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cano C; Dolores R
Expert Opin Pharmacother; 2014 Jan; 15(1):51-60. PubMed ID: 24206031
[TBL] [Abstract][Full Text] [Related]
5. The safety of drug treatments for cervical cancer.
Dueñas-González A; Cetina L; Coronel J; González-Fierro A
Expert Opin Drug Saf; 2016; 15(2):169-80. PubMed ID: 26650333
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cervantes-Madrid D
Expert Opin Emerg Drugs; 2012 Jun; 17(2):203-18. PubMed ID: 22530838
[TBL] [Abstract][Full Text] [Related]
7. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.
Schefter T; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Sause W; Gaffney D;
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):101-5. PubMed ID: 24331655
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A; Cetina L; Coronel J; Martínez-Baños D
Drugs; 2010 Mar; 70(4):403-32. PubMed ID: 20205484
[TBL] [Abstract][Full Text] [Related]
9. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer.
Eifel PJ
Nat Clin Pract Oncol; 2006 May; 3(5):248-55. PubMed ID: 16683003
[TBL] [Abstract][Full Text] [Related]
11. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
[TBL] [Abstract][Full Text] [Related]
12. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS; Tewari KS
Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer.
Jurado M; Martínez-Monge R; García-Foncillas J; Azinovic I; Aristu J; López-García G; Brugarolas A
Gynecol Oncol; 1999 Jul; 74(1):30-7. PubMed ID: 10385548
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.
Rose PG; Ali S; Watkins E; Thigpen JT; Deppe G; Clarke-Pearson DL; Insalaco S;
J Clin Oncol; 2007 Jul; 25(19):2804-10. PubMed ID: 17502627
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
Seol HJ; Ulak R; Ki KD; Lee JM
Tohoku J Exp Med; 2014 Apr; 232(4):269-76. PubMed ID: 24695215
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer.
Borowsky ME; Elliott KS; Pezzullo JC; Santoso P; Choi W; Choi K; Abulafia O
Bull Cancer; 2005 Feb; 92(2):E19-24. PubMed ID: 15749639
[TBL] [Abstract][Full Text] [Related]
20. Targeting CDKN3 in cervical cancer.
Berumen J; Espinosa AM; Medina I
Expert Opin Ther Targets; 2014 Oct; 18(10):1149-62. PubMed ID: 25152075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
